Pharmacy Drugs
Recent Posts
- Alimera Announces Positive Results From The Two Phase 3 FAME(TM) Trials Of Iluvien(R) In Patients With Diabetic Macular Edema
- Lytix Biopharma AS Announces Regulatory Approval By Norwegian And Swedish Authorities To Commence Phase I Clinical Trial Of OncoporeTM In Cancer
- NPA Responds To Quality Accounts Consultation, UK
- Novelos Therapeutics’ (NVLT.OB) CEO Is Eyeing “Revolutionary” Phase III Study Results
- Investigational Dual Orexin Receptor Antagonist Almorexant Meets Primary Endpoint In Two-week Phase III Study Of Primary Insomnia
Random Posts
- Protalix Holds Pre-NDA Meeting With FDA For PrGCD For The Treatment Of Gaucher Disease
- Intrexon Corporation Initiates Phase 1b Clinical Trial In Advanced Melanoma
- Cardium Presents Gene Activated Matrix Technology And Update On Excellarate Clinical Development Program At ASGT Annual Meeting
- Diabetes Drug Shows MS Potential
- Sinovac Files Clinical Trial Application With SFDA For Vaccine Against Hand, Foot, And Mouth Disease
- FDA Okays Ankle Replacement Device
- TAU's Easy-To-Swallow Drug Restores Autoimmune Function In Diabetics
- Low Blood Glucose Levels Do Not Explain Excess Deaths In Accord Trial
- FDA Likely to Approve H1N1 Vaccine In Advance of Data
- NuPathe Reports Positive Phase III Results For Zelrix, A Novel Transdermal Patch For Acute Migraine
Hatwig Receives American Society of Health-System Pharmacists Award Of Excellence
Posted by: admin in Pharmacy Drugs on September 24th, 2009
The American Society of Health-System Pharmacists (ASHP) today honored Christopher A. Hatwig, M.S., FASHP, with the ASHP Board of Directors Award of Excellence for his work to help safety net hospitals provide safe and cost-effective drug therapy to low-income and uninsured patients. Hatwig, vice president of Apexus in Irving, Texas, received the award during ASHP’s Summer Meeting in Rosemont, Ill.
Apexus is responsible for managing the Health Resources and Services Administration’s (HRSA) 340B Prime Vendor Program. Mr. Hatwig works closely with HRSA’s Office of Pharmacy Affairs and the Pharmacy Services Support Center in Washington, D.C. to educate all stakeholders, and to improve the integrity and value of the 340B Drug Pricing Program for the nation’s safety-net providers. Under his leadership, the program generated savings of over $24 million or an average savings of 16 percent below the federal 340B ceiling price on its contracted products in 2008. Apexus is a wholly owned non-profit subsidiary of Provista Inc.
Before joining Apexus, Hatwig was the director of ambulatory pharmacy services and value analysis programs at Parkland Health & Hospital System in Dallas where he practiced for 13 years. At Parkland he managed one of the nation’s largest and more progressive ambulatory pharmacy programs serving the low-income and uninsured. He was responsible for managing Parkland’s network of ambulatory pharmacies, which processed over two million prescriptions annually and operated with a drug expense budget of $65 million.
“Mr. Hatwig’s work with the 340B program ensures that the most vulnerable patients in our country have access to the critical medications that they need and the expertise of pharmacists to guide their use,” said Kevin J. Colgan, M.A., FASHP. “We are pleased to recognize his efforts with the Award of Excellence.”
Hatwig has made numerous presentations on the 340B drug pricing program, innovative ambulatory pharmacy services, and drug cost containment strategies. He has served as chair of the ASHP Council on Administrative Affairs and is a reviewer for the American Journal of Health-System Pharmacy. He is also a member of the Texas Society of Health-System Pharmacists and the Academy of Managed Care Pharmacy.
Mr. Hatwig received his bachelor’s degree in pharmacy from the University of Arkansas and completed residencies in hospital pharmacy and hospital pharmacy administration at the University of Wisconsin, where he also received a master’s degree in hospital pharmacy.
Source
American Society of Health-System Pharmacists
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.